Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Frontera London

- PMLiVE

The first, my last, my everything

The inescapable rise of patient-centricity

- PMLiVE

J&J’s Invokana first SGLT2 to show kidney disease benefits

Could help revival after amputation risk scare

- PMLiVE

J&J’s targeted bladder cancer treatment gets US approval

Balversa is first FGFR inhibitor

- PMLiVE

Allergan wins support against dissident shareholders

Shareholders vote on 1 May

- PMLiVE

Promethera’s liver failure stem cell therapy clears first hurdle

Technique could be alternative to transplant

- PMLiVE

CAR-T player Autolus seeks $100m from follow-on financing

Funds will further develop pipeline

- PMLiVE

Novo Nordisk and Gilead join forces in NASH

Will combine semaglutide with Gilead’s cilofexor and firsocostat

- PMLiVE

Intercept builds its case for Ocaliva in NASH, but safety still an issue

Mixed efficacy and safety results hits NASH frontrunner

- PMLiVE

No-deal risk recedes, but new Brexit delay adds to uncertainty

Delay means industry must sustain no-deal investment

Vertex: a vision of treating all CF patients worldwide draws closer

Its high prices are controversial, but Vertex also embodies the best of biopharma drug development

- PMLiVE

Galderma launches Rosacea awareness campaign

Campaign comes on the back of Rosacea Awareness Month

- PMLiVE

Sanofi joins Lilly in insulin price cut, but lawmakers have lost patience

Insulin price nearly tripled between 2002 and 2013

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links